Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 7/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15889188 | 0.89 | CYP2D6 (0.52) | CYP2D6KCNH2CYP4F2CYP4A11SMN1; SMN2 | |
| SCHEMBL15876078 | 0.86 | SLC7A5 (0.52) | CYP2D6KCNH2CYP4F2CYP4A11 | |
| SCHEMBL3012856 | 0.81 | CYP4F2 (0.54) | CYP2D6CYP4F2CYP4A11SMN1; SMN2NPC1 | |
| SCHEMBL15344564 | 0.79 | CYP4F2 (0.61) | CYP2D6CYP4F2CYP4A11SMN1; SMN2NPC1 | |
| SCHEMBL6387163 | 0.78 | TDP1 (0.54) | CYP2D6ALDH1A1 | |
| SCHEMBL3000441 | 0.77 | CYP4F2 (0.46) | CYP2D6CYP4F2CYP4A11SMN1; SMN2NPC1 | |
| SCHEMBL7456281 | 0.77 | SPR (0.51) | CYP2D6KCNH2 | |
| SCHEMBL22621227 | 0.77 | SMN1; SMN2 (0.48) | CYP2D6CYP4F2CYP4A11SMN1; SMN2NPC1 | |
| SCHEMBL15888238 | 0.76 | SMN1; SMN2 (0.55) | CYP2D6CYP4F2CYP4A11SMN1; SMN2NPC1 | |
| SCHEMBL10706157 | 0.76 | L3MBTL1 (0.57) | CYP2D6CYP4F2CYP4A11SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250195462-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | MILESTONE PHARMACEUTICALS INC (CA) | 2025-06-19 | — | — | US | disclosed |
| US-20240115543-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | MILESTONE PHARMACEUTICALS INC (CA) | 2024-04-11 | — | — | US | disclosed |
| US-20230255923-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | MILESTONE PHARMACEUTICALS INC (CA) | 2023-08-17 | — | — | US | disclosed |
| US-20220142963-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | MILESTONE PHARMACEUTICALS INC (CA) | 2022-05-12 | — | — | US | disclosed |
| US-20210315855-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | MILESTONE PHARMACEUTICALS INC (CA) | 2021-10-14 | — | — | US | disclosed |
| US-20210059972-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | MILESTONE PHARMACEUTICALS INC (CA) | 2021-03-04 | — | — | US | disclosed |
| US-20200230097-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | MILESTONE PHARMACEUTICALS INC (CA) | 2020-07-23 | — | — | US | disclosed |
| US-20190142781-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | MILESTONE PHARMACEUTICALS INC (CA) | 2019-05-16 | — | — | US | disclosed |
| US-10010522-B2 | Short acting phenylalkylamine calcium channel blockers and uses thereof | MILESTONE PHARMACEUTICALS INC. (CA) | 2018-07-03 | — | — | US | disclosed |
| US-10010524-B2 | Short acting phenylalkylamine calcium channel blockers and uses thereof | MILESTONE PHARMACEUTICALS INC. (CA) | 2018-07-03 | — | — | US | disclosed |
| US-10010523-B2 | Short acting phenylalkylamine calcium channel blockers and uses thereof | MILESTONE PHARMACEUTICALS INC. (CA) | 2018-07-03 | — | — | US | disclosed |
| US-20170312241-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | ACQUIOM AGENCY SERVICES, LLC | 2017-11-02 | — | — | US | disclosed |
| US-20170312242-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | ACQUIOM AGENCY SERVICES, LLC | 2017-11-02 | — | — | US | disclosed |
| US-20170312243-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | ACQUIOM AGENCY SERVICES, LLC | 2017-11-02 | — | — | US | disclosed |
| US-9737503-B2 | Short acting phenylalkylamine calcium channel blockers and uses thereof | MILESTONE PHARMACEUTICALS INC. (CA) | 2017-08-22 | — | — | US | disclosed |
| US-20160374982-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | ACQUIOM AGENCY SERVICES, LLC | 2016-12-29 | — | — | US | disclosed |
| EP-2170050-B1 | Short acting phenylalkylamine calcium channel blockers and uses thereof | MILESTONE PHARMACEUTICALS INC (CA) | 2014-06-18 | — | — | EP | disclosed |
| EP-2170050-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | Milestone Pharmaceuticals Inc. (CA) | 2010-04-07 | — | — | EP | disclosed |
| WO-2008156820-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | MILESTONE PHARMACEUTICALS INC. (CA) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200230097-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | ORAI1, ATP2A1, RYR2 | CYP2D6 3026/4885KCNH2 61/4885CYP4F2 3383/4885 |
| US-20240115543-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | ORAI1, ATP2A1, RYR2 | CYP2D6 3026/4885KCNH2 61/4885CYP4F2 3383/4885 |
| US-20220142963-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | ORAI1, ATP2A1, RYR2 | CYP2D6 3026/4885KCNH2 61/4885CYP4F2 3383/4885 |
| US-20190142781-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | ORAI1, ATP2A1, RYR2 | CYP2D6 3026/4885KCNH2 61/4885CYP4F2 3383/4885 |
| US-20230255923-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | ORAI1, ATP2A1, RYR2 | CYP2D6 3026/4885KCNH2 61/4885CYP4F2 3383/4885 |
| US-20160374982-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | ORAI1, ATP2A1, RYR2 | CYP2D6 3026/4885KCNH2 61/4885CYP4F2 3383/4885 |
| US-20210315855-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | ORAI1, ATP2A1, RYR2 | CYP2D6 3026/4885KCNH2 61/4885CYP4F2 3383/4885 |
| US-20210059972-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | ORAI1, ATP2A1, RYR2 | CYP2D6 3026/4885KCNH2 61/4885CYP4F2 3383/4885 |
| US-20170312243-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | ORAI1, ATP2A1, RYR2 | CYP2D6 3026/4885KCNH2 61/4885CYP4F2 3383/4885 |
| US-10010524-B2 | Short acting phenylalkylamine calcium channel blockers and uses thereof | ORAI1, ATP2A1, RYR2 | CYP2D6 3026/4885KCNH2 61/4885CYP4F2 3383/4885 |
| US-10010522-B2 | Short acting phenylalkylamine calcium channel blockers and uses thereof | ORAI1, ATP2A1, RYR2 | CYP2D6 3026/4885KCNH2 61/4885CYP4F2 3383/4885 |
| US-20170312241-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | ORAI1, ATP2A1, RYR2 | CYP2D6 3026/4885KCNH2 61/4885CYP4F2 3383/4885 |
| US-10010523-B2 | Short acting phenylalkylamine calcium channel blockers and uses thereof | ORAI1, ATP2A1, RYR2 | CYP2D6 3026/4885KCNH2 61/4885CYP4F2 3383/4885 |
| US-20170312242-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | ORAI1, ATP2A1, RYR2 | CYP2D6 3026/4885KCNH2 61/4885CYP4F2 3383/4885 |
| US-20250195462-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | ORAI1, ATP2A1, RYR2 | CYP2D6 3026/4885KCNH2 61/4885CYP4F2 3383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.